Skip to content
LISTE DE DIFFUSION
Linkedin page opens in new window
AB Science
Discipline serving the patients
AB Science
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in sickle cell disease
    • Masitinib in neurodegenerative disorders
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Sickle Cell Disease
      • Alzheimer’s Disease
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webcasts
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
      • Articles of Incorporation
      • Board of Directors Charter
      • Information document
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact
  • FR
  • EN
Search:
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in sickle cell disease
    • Masitinib in neurodegenerative disorders
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Sickle Cell Disease
      • Alzheimer’s Disease
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webcasts
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
      • Articles of Incorporation
      • Board of Directors Charter
      • Information document
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact

Monthly Archives: October 2026

You are here:
  1. Home
  2. 2026
  3. October

Revenues for the first half of 2026 and update on AB Science’s activities

2026By Alexis BERNARD9 October 2026

09/10/2026 – AB Science today reports its revenues for the first half of 2026 and provides an update on its activities

© 2026 AB SCIENCE
Go to Top